| Literature DB >> 33746449 |
Deepu David1, Chundamannil E Eapen2.
Abstract
Of the currently available drugs tested to treat nonalcoholic fatty liver disease (NAFLD), the most efficacious drugs are pioglitazone (an insulin sensitizer) and vitamin E (an antioxidant). By targeting insulin resistance, the key pathogenic mechanism underlying metabolic syndrome and NAFLD, pioglitazone maybe the preferred drug to treat NAFLD. As we await the results of research trials into multiple new drugs to treat NAFLD, when should we use the currently available patients to treat NAFLD at the present time? To date, no drug has been approved by regulatory agency specifically to treat NAFLD. However, many drugs have been approved to treat other components of metabolic syndrome such as diabetes mellitus and dyslipidemia. Are we underutilizing the currently available drugs to treat NAFLD? Herein, we review the benefits and concerns of the use of these currently available drugs to treat NAFLD and suggest clinical scenarios, wherein the clinician should consider using these drugs.Entities:
Keywords: NAFLD; NASH; nonalcoholic fatty liver disease; treatment of NAFLD
Year: 2020 PMID: 33746449 PMCID: PMC7953000 DOI: 10.1016/j.jceh.2020.09.001
Source DB: PubMed Journal: J Clin Exp Hepatol ISSN: 0973-6883